{"schema_version":"secwatch.filing_event.v1","accession":"0001214659-25-014818","form_type":"8-K","ticker":"ALZN","cik":"0001677077","company_name":"Alzamend Neuro, Inc.","filed_at":"2025-10-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.123284+00:00","generated_at":"2026-05-17T04:11:55.959665+00:00","sec_items":["3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Alzamend Neuro issues 361,743 shares on Series B Preferred conversion","bullets":["Between Oct 1-8, 2025, 361,743 shares issued upon conversion of ~839.2 Series B Convertible Preferred shares.","Shares issued under Section 4(a)(2) exemption from registration.","As of Oct 8, 2025, total common shares outstanding: 3,801,604.","Conversion increases outstanding share count by roughly 10.5% from prior level."],"urls":{"canonical":"https://secwatch.observer/filing/0001214659-25-014818","json":"https://secwatch.observer/filing/0001214659-25-014818.json","markdown":"https://secwatch.observer/filing/0001214659-25-014818.md","text":"https://secwatch.observer/filing/0001214659-25-014818.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677077/000121465925014818/0001214659-25-014818-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677077/000121465925014818/o1082528k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:11:55.959665+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}